On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:EW) detailed its strategy for sustained long-term growth and innovations in structural heart therapies.

BofA analyst Travis Steed upgraded Edwards Lifesciences (EW) to Buy from Neutral with a price target of $90, up from $82. The path in 2025 “skews higher” given several potential catalysts and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

On Monday, BofA Securities adjusted its stance on shares of Edwards Lifesciences (NYSE:EW), shifting from a Neutral to a Buy rating, and increased the price target to $90 from the previous $82.

Many of the top large-cap device makers reported relatively rosy fourth-quarter earnings while issuing 2023 guidance that was above analyst expectations.

After hours: 19 December at 18:14:47 GMT-5 ...

Check out the best internal and external product catalog templates for Excel, Google Sheets, Notion, Trello, Airtable, and more. Product catalog templates can act as an internal database for ...